307 related articles for article (PubMed ID: 32716320)
1. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Isaacson SH; Coate B; Norton J; Stankovic S
J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
[TBL] [Abstract][Full Text] [Related]
2. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
[TBL] [Abstract][Full Text] [Related]
3. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
4. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
[TBL] [Abstract][Full Text] [Related]
5. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Norton JC; Chi-Burris K; Demos G
CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
[TBL] [Abstract][Full Text] [Related]
6. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
DeKarske D; Alva G; Aldred JL; Coate B; Cantillon M; Jacobi L; Nunez R; Norton JC; Abler V
J Parkinsons Dis; 2020; 10(4):1751-1761. PubMed ID: 32804101
[TBL] [Abstract][Full Text] [Related]
9. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
Ballard C; Youakim JM; Coate B; Stankovic S
J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
[TBL] [Abstract][Full Text] [Related]
10. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
Bugarski-Kirola D; Arango C; Fava M; Nasrallah H; Liu IY; Abbs B; Stankovic S
Lancet Psychiatry; 2022 Jan; 9(1):46-58. PubMed ID: 34861170
[TBL] [Abstract][Full Text] [Related]
12. Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
[TBL] [Abstract][Full Text] [Related]
13. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.
Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N
J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
15. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
16. Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
Schubmehl S; Sussman J
Am J Geriatr Psychiatry; 2018 Oct; 26(10):1007-1011. PubMed ID: 30072306
[TBL] [Abstract][Full Text] [Related]
17. Can pimavanserin help patients with Parkinson disease psychosis?
de la Cruz J; Canal C
JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736
[TBL] [Abstract][Full Text] [Related]
18. Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial.
Weintraub D; Espay AJ; Sharma VD; Tariot PN; Abler V; Pathak S; Stankovic S
Parkinsonism Relat Disord; 2024 Feb; 119():105951. PubMed ID: 38113700
[TBL] [Abstract][Full Text] [Related]
19. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
[TBL] [Abstract][Full Text] [Related]
20. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
